Cosmetic Surgery Forum celebrates a decade of success. The meeting, featuring a panel of experts in both medical and cosmetic dermatology, wrapped up on Saturday and is already announcing plans for 2019. When it comes to psoriatic arthritis, prescribers should treat to target, new guidelines from the National Psoriasis Foundation and the American College of Rheumatology conclude. Revance Therapeutics may submit a Biologics License Application for long-acting neuromodulator daxibotulinumtoxinA for Injection, known as RT002, in the first half of next year.
DermWire.com, Diane Berson, MD, FAAD, Joel L. Cohen, MD, Neal Bhatia, MD, FAAD, Rajani Katta, MD, Seemal R. Desai, MD, Shari Lipner, MD